Medications
CLASS: A

PROTOCOL(S) USED IN:
Seizure

PHarmacology AND ACTIONS:
Non-narcotic analgesic and antipyretic

INDICATIONS:
Reduction of fever associated with febrile seizures in the pediatric patient.

CONTRAINDICATIONS:
A. Hypersensitivity
B. DO NOT use with any other products that contain acetaminophen

SIDE EFFECTS AND NOTES:
May be administered via rectal suppository (same dose) if patient is vomiting, the patient's gag reflex is absent or in question or the patient is not alert. Can be given up to every 4 hours. Do not exceed five doses a day.

DOSING CHART:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Age</th>
<th>80mg Tablets</th>
<th>160mg/tsp Elixir</th>
<th>80mg/0.8ml Drops</th>
<th>Mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-11 lbs</td>
<td>0-3 mos</td>
<td>---</td>
<td>¼ tsp</td>
<td>.4ml</td>
<td>40mg</td>
</tr>
<tr>
<td>12-17 lbs</td>
<td>4-11 mos</td>
<td>---</td>
<td>½ tsp</td>
<td>.8ml</td>
<td>80mg</td>
</tr>
<tr>
<td>18-23 lbs</td>
<td>11-23mos</td>
<td>1 ½ tab</td>
<td>½ tsp</td>
<td>1.2ml</td>
<td>120mg</td>
</tr>
<tr>
<td>24-35 lbs</td>
<td>2-3yrs</td>
<td>2 tabs</td>
<td>1 tsp</td>
<td>1.6ml</td>
<td>160mg</td>
</tr>
<tr>
<td>36-47 lbs</td>
<td>4-5yrs</td>
<td>3 tabs</td>
<td>1 ½ tsp</td>
<td>2.4ml</td>
<td>240mg</td>
</tr>
<tr>
<td>48-59 lbs</td>
<td>6-8yrs</td>
<td>4 tabs</td>
<td>2 tsp</td>
<td>3.2ml</td>
<td>320mg</td>
</tr>
<tr>
<td>60-71 lbs</td>
<td>9-10yrs</td>
<td>5 tabs</td>
<td>2 ½ tsp</td>
<td>4.0ml</td>
<td>400mg</td>
</tr>
<tr>
<td>72-95 lbs</td>
<td>11-12yrs</td>
<td>6 tabs</td>
<td>3 tsp</td>
<td>4.8ml</td>
<td>480mg</td>
</tr>
</tbody>
</table>
CLASS: A

PHARMACOLOGY AND ACTIONS:
Activated charcoal adsorbs toxic substances ingested and inhibits GI adsorption by forming an effective barrier between the particulate material and the gastrointestinal mucosa. The effect is greatest if used within one hour of ingestion. It can absorb up to 99% of another substance to render it inert.

INDICATIONS:
Management of poisoning or overdose of many substances.

CONTRAINDICATIONS:
A. Patients with altered mental status or the inability to maintain their own airway.
B. Patients who have aspirated or with a potential for aspiration.

PRECAUTIONS:
A. Activated charcoal may be ineffective in some ingestions.
B. Milk, ice cream and other dairy products will decrease the absorption capacity substantially.

SIDE EFFECTS AND NOTES:
May cause nausea, vomiting and black stool. May inactivate other drugs administered orally. DO NOT administer until ipecac-induced emesis has stopped. Contact medical or poison control before administration for petroleum or caustic ingestion. Often used with magnesium citrate.

ADULT DOSING:
Poisoning & overdose -
- 1-2 grams/kg premixed
- If needed to be mixed, ratio of 1:4 parts
- Administer orally or via nasogastric tube

PEDIATRIC DOSING:
Same as adult.
CLASS: A

PROTOCOLS USED IN: ACLS

PHARMACOLOGY AND ACTIONS:
Adenosine is a naturally occurring nucleoside that has the ability to slow conduction through the AV node. Since most cases of PSVT involve AV nodal re-entry, adenosine is capable of interrupting the AV nodal circuit and stopping the tachycardia, restoring normal sinus rhythm. It is eliminated from the circulation rapidly and has a half-life in the blood of less than ten seconds.

INDICATIONS:
To convert PSVT to a normal sinus rhythm, including PSVT that is associated with accessory bypass tracts (e.g. Wolff-Parkinson-White Syndrome).

CONTRAINDICATIONS:
A. Second or third degree heart block.
B. Sick Sinus Syndrome
C. Known hypersensitivity
D. Does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia

PRECAUTIONS:
A. When doses larger than 12 mg are given by injection there may be a decrease in blood pressure secondary to a decrease in vascular resistance.
B. The effects of Adenosine are antagonized by methylxanthines such as Theophylline and caffeine. Larger doses of Adenosine may be required.
C. Adenosine effects are potentiated by dipyridamole (Persantine) resulting in prolonged asystole.
D. In the presence of carbamazepine (Tegretol), high degree heart block may occur.
E. Adenosine is not effective in converting atrial fibrillation, atrial flutter or ventricular tachycardia.
F. All doses of adenosine should be reduced to one-half (50%) in the following clinical settings:
   a. History of cardiac transplantation.
   b. Patients who are on carbamazepine (Tegretol) and dipyridamole (Persantine).
   c. Administration through any central line.

SIDE EFFECTS AND NOTES:
May cause facial flushing, shortness of breath, chest pressure, nausea, headache and lightheadedness.

ADULT DOSING:
PSVT -
6 mg rapid IV. May repeat with 12 mg IV x 2 if patient fails to convert after 6 mg dose. Use a large proximal IV site with fluid bolus flush.
PEDIATRIC DOSING:

PSVT -

0.1 mg/kg rapid IV. May repeat with 0.2 mg/kg once if patient fails to convert after first dose. Use a large proximal IV site with fluid bolus flush. IO: 6mg, max dose of 12 mg.
OLMC REQUIRED:
For use in hyperkalemia patients including crush injury.

SUPPLIED:  2.5 mg / 3 ml vial.

PHARMACOLOGY AND ACTIONS:
Albuterol is a potent, relatively selective Beta-2 adrenergic bronchodilator and is associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate sensitivity from cells, especially MAST cells. The onset of improvement in pulmonary function is within 2 – 15 minutes after the initiation of treatment and the duration of action is from 4 – 6 hours. Albuterol has occasional Beta-1 overlap with clinically significant cardiac effects.

INDICATIONS:
A. To treat bronchial asthma and reversible bronchial spasm that occurs with chronic obstructive pulmonary disease.
B. To treat hyperkalemia.

CONTRAINDICATIONS:
None in the prehospital setting.

PRECAUTIONS:
A. The patient's rhythm should be observed for arrhythmias. Stop treatment if frequent PVC’s develop or any tachyarrhythmias other than sinus tachycardia appear or if heart rate increases by more than 20 beats/minute.
B. Paradoxical bronchospasm may occur with excessive administration.

SIDE EFFECTS AND NOTES:
Clinically significant arrhythmias may occur, especially in patients with underlying cardiovascular disorders such as coronary insufficiency and hypertension.

ADULT DOSING:
- Respiratory distress -
  2.5 mg via nebulizer. Repeat as needed.
- Hyperkalemia -
  10 mg via nebulizer. OLMC contact required.
- Hyperkalemia secondary to crush injury -
  OLMC contact required.

PEDIATRIC DOSING:
Same as adult
CLASS: A

PROTOCOL(S) USED IN: ACLS, Chest Pain

PHARMACOLOGY AND ACTIONS:
Blocks formation of thromboxane A2 which causes platelets to aggregate and arteries to constrict.

INDICATIONS:
Chest pain suspected of being cardiac in origin.

CONTRAINDICATIONS:
A. Known hypersensitivity
B. Relatively contraindicated in patients with history of active ulcer disease or asthma.

SIDE EFFECTS AND NOTES:
A. Higher doses can interfere with prostacyclin production and interfere with positive benefits.
B. Aspirin alone, started within 24 hours of the onset of an acute MI, reduced overall mortality to almost the same degree as thrombolytic agents.

ADULT DOSING:
Chest pain (acute myocardial infarction)
2-4 chewable baby aspirin 162-324mg PO.

PEDIATRIC DOSING:
Not indicated for pediatric patients
CLASS: A

PROTOCOLS USED IN: Respiratory Distress, Asthma

PHARMACOLOGY AND ACTIONS:
Ipratropium is an atropine derivative used for inhalation therapy. For severe asthma, Ipratropium taken in addition to a short acting beta agonist (such as Albuterol) can provide greater bronchodilation and clinical benefit than the beta agonist alone. It has no anti-inflammatory effects and does not decrease bronchial hyper-responsiveness.

INDICATIONS:
Bronchial Asthma and reversible bronchial spasm that occur with chronic pulmonary disease.

CONTRAINDICATIONS:
Stop treatment if pulse increases by 20 bpm, frequent PVCs develop, any tachyarrhythmias other than sinus tachycardia appear, chest pain, apnea, nausea or vomiting or increased shortness of breath occur.

PRECAUTIONS:
Ipratropium in the meter dose inhaler and auto-inhaler formulations should not be administered to individuals allergic to soy lecithin or related food products (e.g. soy beans, peanuts). The nebulized formulation may be administered to these patients.

SIDE EFFECTS AND NOTES:
A. Patients with COPD should be monitored carefully for CO2 retention and decreased levels of consciousness.
B. Paradoxical bronchospasm may occur with excessive administration.
C. Skeletal muscle tremors.
D. Albuterol should be used with caution in pregnancy.
E. Continually assess patient’s respiratory rate, effort and lung sounds.

ADULT DOSING:
Nebulizer:
2.5mg mixed in 3ml of normal saline for a concentration of 0.83mg/ml with at least 6 lpm of oxygen flow. Coach patient to inhale slowly and exhale passively through nose.

Metered Dose Inhaler (MDI)-delivers 90mcg per puff
Assemble one BVM, one AeroChamber, oxygen tubing and Albuterol inhaler. Begin with two Albuterol puffs into chamber and assist patient’s ventilations using the BVM and high flow oxygen. After one minute, repeat with two puffs. Repeat every two minutes if improvement is not noted. DO NOT EXCEED 20 PUFFS.

PEDIATRIC DOSING:
≤ 1 year of age: Nebulized dosage of 0.03ml/kg with a max dose of 1ml.
Amiodarone (Cordarone®) – 20.055

CLASS: A

PROTOCOL(S) USED IN: ACLS

PHARMACOLOGY AND ACTIONS:
A. Antiarrhythmic
B. Prolongation of the myocardial cell-action potential duration & refractory period.
C. Noncompetitive alpha and beta-adrenergic inhibition.
D. Blocks sodium channels and, to some extent, the calcium channels.

INDICATIONS:
A. Refractory sustained ventricular fibrillation/pulseless ventricular tachycardia.
B. Ventricular Tachycardia with a pulse.

CONTRAINDICATIONS:
A. None when given in the cardiac arrest setting.

SIDE EFFECTS AND NOTES:
A. Hypotension
B. Bradycardia
C. Congestive heart failure
D. AV Block
E. Shaking vials will cause foaming of the medication

ADULT DOSING:
- Pulseless rhythms; 300mg/6ml rapid IV push followed by a 10ml NS flush, may repeat at 150 mg/3ml IV push.
- With Pulse; 150mg in 100ml of NS over 10 minutes

PEDIATRIC DOSING:
Vfib/Vtach—5 mg/kg per AHA guidelines
**CLASS:** A  

**PROTOCOL(S) USED IN:** ACLS, poisoning; organophosphates  

**PHARMACOLOGY AND ACTIONS:**  
A. Muscarine-cholinergic blocking agent.  
B. Increases heart rate by blocking vagal response.  
C. Increases conduction through A-V node and increases ventricular sensitivity to atrial impulses.  
D. Reduces motility and tone of GI tract.  
E. Reduces action and tone of bladder which may cause urinary retention.  
F. Dilates pupils.  

**INDICATIONS:**  
A. Symptomatic bradycardias, 2\textsuperscript{nd} and 3\textsuperscript{rd} degree heart blocks and pacemaker failure.  
B. Organophosphate and nerve gas poisoning.  

**CONTRAINDICATIONS:**  
A. Atrial fibrillation and atrial flutter  
B. Glaucoma  

**SIDE EFFECTS AND NOTES:**  
A. Bradycardia maybe beneficial in the AMI setting. Administer only if there are signs of hypoperfusion (chest pain, low blood perfusion, altered mental status).  
B. In organophosphates poisoning, massive doses of 10-20mg or more may be needed.  
C. Titrate dose by watching patient response.  

**ADULT DOSING:**  
**Symptomatic Bradycardia:**  
0.5-1.0mg IV push, repeat if needed in 3-5 minute intervals to a maximum dose of .03-.04mg/kg  

**PEDIATRIC DOSING:**  
**Symptomatic Bradycardia:**  
.01-.02mg/kg
CLASS: A

PROTOCOL(S) USED IN: ACLS

PHARMACOLOGY AND ACTIONS:
Increases the force of myocardial contraction by initiation of myofibril shortening. The positive inotropic effects and vasoconstricting effects produce a rise in systemic arterial pressure.

INDICATIONS:
In cardiac arrest setting:
A. Hyperkalemia secondary to renal failure.
B. Hypocalcemia due to multiple blood transfusions.
C. Known or suspected calcium channel blocker overdoses.

Hyperkalemia not in cardiac arrest

CONTRAINDICATIONS:
A. CANNOT BE ADMINISTERED WITH SODIUM BICARBONATE
B. In presence of sodium bicarbonate, calcium salts will precipitate as carbonates.

SIDE EFFECTS AND NOTES:
A. Extremely important to flush the IV line between administration of sodium bicarbonate and calcium chloride to avoid precipitation.
B. May produce coronary and cerebral artery spasms.
C. Should be used with caution in patients receiving digitalis; may precipitate toxicity.

ADULT DOSING:

Cardiac Arrest:
A. 2-4mg/kg of 10% (100mg/cc) solution slow IV push.
B. May be repeated as necessary.

Non-Cardiac Arrest Hyperkalemia, 10 ml
OLMC REQUIRED:
Suspected calcium channel blocker overdose except in cardiac arrest.

SUPPLIED: 98 mg (4.65 mEq) of 10% solution / 10 ml vial.

PHARMACOLOGY AND ACTIONS:
Calcium is the most common cation in the human body. The majority of the body stores of calcium are located in bone. It plays an important role in many physiologic functions and is essential for proper nerve and muscle function.

INDICATIONS:
A. Suspected calcium channel Blocker overdose.
B. Hyperkalemia.

CONTRAINDICATIONS:
A. Hypercalcemia and hypercalciuria (hyperthyroidism, Vitamin D overdose, bone metastases).
B. Patients on Digoxin.

PRECAUTIONS:
A. Extravasation of Calcium salts will cause necrosis of tissue. The IV should be secured and free blood return into the syringe should be checked 2-3 times during administration. If extravasation does occur, immediately stop administration.
B. Administer slowly (no faster than 2ml/min) and stop if patient complains of distress. Inject using a small needle in a large vein.
C. Calcium Gluconate will precipitate if mixed with Sodium Bicarbonate. Flush catheter completely before administering one medication after another.

SIDE EFFECTS AND NOTES:
A. Rapid injection of Calcium Gluconate may cause vasodilatation, decreased blood pressure, bradycardia, cardiac arrhythmias, syncope and cardiac arrest.
B. One vial of 10 ml Calcium Gluconate 10% contains 1 gram of calcium gluconate salt (= 93 mg elemental calcium or 4.6 mEq calcium or 2.3 mmol calcium)

ADULT DOSING:
Hyperkalemia, calcium channel blocker overdose -
1 gm slow IV/IO over 5 – 10 minutes. Use a proximal port.

PEDIATRIC DOSING:
Hyperkalemia, calcium channel blocker overdose -
0.5 ml/kg slow IV/IO over 5 – 10 minutes. Use a proximal port. Max dose 10 ml.
CLASS: A

PROTOCOL(S) USED IN: Altered mental status/coma, Hypoglycemia

PHARMACOLOGY AND ACTIONS:
A. Glucose is used by the body as quick energy.
B. Its use is regulated by insulin, which stimulates storage of glucose from the bloodstream lowering blood glucose levels.
C. Glucagon, which mobilizes stored glucose into the bloodstream, raises glucose levels.

INDICATIONS:
A. Hypoglycemic states usually associated with insulin shock in diabetes.
B. The unconscious patient, when history is unobtainable but after a blood glucose test.
C. In patients with any focal or partial neurologic deficit or altered mental status.
D. Hypothermia, generalized.

CONTRAINDICATIONS:
None

SIDE EFFECTS AND NOTES:
A. Determine blood glucose level prior to administration.
B. If glucose monitor is unavailable, draw blood for a red top tube (5ml).
C. Extravasation of dextrose will cause necrosis of tissue.
D. IV should be secured in a large vein and free return of blood into the syringe or tubing should be checked 2-3 times prior to and during administration.
E. If extravasation does occur, immediately dilute with up to 10ml Lidocaine 1% or Normal Saline injected SQ into extravasated area.
F. Dextrose may precipitate Wernicke’s encephalopathy in alcoholics. If suspected, give Thiamine 50-100mg IV prior to administration of dextrose.
G. Do not draw blood for glucose determination from site proximal to an IV containing glucose or dextrose.
H. Effect is delayed in elderly patients with poor circulation.
I. Recheck blood glucose level 5 minutes after administration.

ADULT DOSING:
Hypoglycemia/Altered mental status - 12.5 - 25 grams of Dextrose 50% IV into large, secure vein if patient isn’t able to tolerate oral glucose.

PEDIATRIC DOSING –
Hypoglycemia/Altered mental status - Repeat dose as needed.
- Infants < 10 kg (birth to 1 year) with CBG < 45 mg%:
  - Give 2.5 - 5 ml/kg of dextrose 10%.
- Children 10 kg – 35kg with CBG < 60 mg%:
  - Give 2 - 4 ml/kg of dextrose 25%.
CLASS: A

PROTOCOL(S) USED IN: ACLS Tachycardia

PHARMACOLOGY AND ACTIONS:
A calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, decreasing myocardium contractility and oxygen demand.

INDICATIONS:
A. Rapid atrial fibrillation or atrial flutter.

CONTRAINDICATIONS:
A. Sick sinus syndrome or second or third degree AV block in the absence of an artificial pacemaker.
B. Systolic BP below 90 mmHg.
C. Wolff-Parkinson-White Syndrome or patients with ventricular tachycardia.

SIDE EFFECTS AND NOTES:
A. Headache, dizziness
B. Arrhythmias, bradycardia, heart failure, AV block-abnormal ECG.
C. Hypotension, flushing
D. Nausea, constipation, abdominal discomfort

ADULT DOSING:
A. .25mg/kg slow IV push.
B. If no response, .35mg/kg slow IV push after 15 minutes.
CLASS: A

PROTOCOL(S) USED IN: Anaphylaxis

PHARMACOLOGY AND ACTIONS:
A. Antihistamine which blocks action of histamines released from cells during an allergic reaction.
B. Direct CNS effects which include stimulant, or more commonly, depressant depending on individual variation.
C. Anticholinergic.

INDICATIONS:
A. Allergic reaction
B. Acute dystonic reactions to antipsychotic medications
C. Adjunctive therapy for anaphylaxis.

CONTRAINDICATIONS:
Relative contraindication for pregnant or lactating females.

SIDE EFFECTS AND NOTES:
A. Sedation, blurred vision, anticholinergic effects.
B. May enhance effects of alcohol or other depressants.
C. Is NOT the first line drug for allergic reactions.

ADULT DOSING:
Anaphylaxis, extrapyramidal symptoms -
25-50mg slow IV push/IM

PEDIATRIC DOSING:
Anaphylaxis, extrapyramidal symptoms -
1-2mg/kg slow IV or IO push/IM
CLASS: C

PROTOCOL(S) USED IN: ACLS

PHARMACOLOGY AND ACTIONS:

A. Chemical precursor of epinephrine which occurs naturally in man.
B. Has both alpha- and beta- receptor stimulating actions depending upon the dose.
C. 1-2 mcg/kg: dilates renal and mesenteric vessels.
D. 2-10 mcg/kg: beta effects on heart which usually increase cardiac output without increasing heart rate or blood pressure.
E. 10-20 mcg/kg: alpha peripheral effects cause peripheral vasoconstriction and increase blood pressure.
F. 20-40 mcg/kg: alpha effects reverse dilation of renal and mesenteric vessels resulting in decreased flow.

INDICATIONS:
A. Primary indication is cardiogenic shock.
B. May be useful in other forms of shock, except hypovolemic.

CONTRAINDICATIONS:
A. Hypovolemic shock
B. Decrease or stop infusion if tachyarrhythmias or HTN occur.

SIDE EFFECTS AND NOTES:
A. Ectopic beats, N/V, angina, VT, VF, HTN, headache, ischemia, AMI
B. Can precipitate hypersensitivity crisis in susceptible individuals especially those on MAO inhibitors.
C. Best administered by an infusion pump to accurately regulate rate.
D. Rule out hypovolemic shock and treat with appropriate fluids before administration of dopamine.
E. Should not be added to sodium bicarbonate or other alkaline solutions since dopamine will be deactivated in alkaline solutions.

ADULT DOSING:
Infusion rate should start between 2-5mcg/kg/min, gradually increasing to 10-20 mcg/kg/min until desired effect is achieved. Use microdrip chamber only.

PEDIATRIC DOSING:
Same as adult.
CLASS: A

PROTOCOL(S) USED IN: Anaphylaxis, ACLS, Asthma, Respiratory Distress

PHARMACOLOGY AND ACTIONS:
A. Catecholamine with alpha and beta effects.
B. Increased heart rate, arterial blood pressure, systemic vascular resistance, automaticity, myocardial O2 consumption and myocardial contractile force.
C. Potent bronchodilator.

INDICATIONS:
A. Ventricular fibrillation
B. Asystole
C. Pulseless Electrical Activity
D. Systemic allergic reactions
E. Asthma in patients under 50 years of age

CONTRAINDICATIONS:
Use caution in patients with peripheral vascular insufficiency.

SIDE EFFECTS AND NOTES:
A. Anxiety, tremor, headache, tachycardia, palpitations, PVCs, angina and HTN
B. Should not be added directly bicarbonate infusion; catecholamine may be partially deactivated by alkaline solutions.
C. When used for allergic reactions, increased cardiac work may precipitate angina and/or MI in susceptible individuals.
D. Wheezing in an elderly patient is considered pulmonary edema or pulmonary embolus until proven otherwise.

ADULT DOSING:
Cardiac Arrest Dosing Options:
  a. 1.0mg (1:10,000) IV every 3-5 minutes during arrest.
  b. 2-5 mg (1:1,000 diluted in 10ml NS) every 3-5 minutes.
  c. .01mg/kg (1:1,000 diluted in 10ml NS) every 3-5 minutes
  d. May be given via ET at 2-2.5 times IV dose.
  e.

Allergic reaction, anaphylaxis shock, laryngeal edema, severe asthma:
  a. .3-.5mg (1:1,000) IM
  b. 2-3ml (1:10,000) IV over 30-60 seconds.

PEDIATRIC DOSING:
Cardiac Arrest -
  a. 0.01 mg/kg (1:10,000) IV/O every 5 minutes

Allergic reaction, anaphylaxis shock, severe asthma -
  a. .01mg/kg (1:1,000) IM
  b. 1-2ml (1:10,000) IV over 30-60 seconds

Croup/Epiglotitis
  a. In patients 6 months to 6 years of age with audible stridor at rest, give 3 ml epinephrine 1:1,000 via nebulizer.
CLASS: A

PROTOCOL(S) USED IN: RSI

PHARMACOLOGY AND ACTIONS:
Exact mechanism of action unknown; may have GABA-like effects, depresses brain stem reticular formation activity and produces hypnosis.

INDICATIONS:
RSI in the hyposensitive patient.

CONTRAINDICATIONS:
Known hypersensitivity to drug/class/components

SIDE EFFECTS AND NOTES:
A. The most frequent adverse reactions are transient venous pain on injection and transient skeletal muscle movements.
B. Etomidate may also cause nausea and/or vomiting.
C. Caution in elderly patients.

ADULT DOSING:
Induction agent for rapid sequence intubation -
0.3 mg / kg IV/IO slow push.

PEDIATRIC DOSING:
Same as adult
CLASS: A

PROTOCOL(S) USED IN: Trauma, RSI, Amputation, Burns, Chest Pain, Abd Pain

PHARMACOLOGY AND ACTIONS:
Fentanyl is a pure opioid analgesic used to manage pain.

INDICATIONS:
A. Pain management
B. Extremity Fractures
C. Back and neck injuries when sedation/pain relief is necessary to prevent a patient from moving around and potentially injuring themselves.
D. Burns
E. Trauma

CONTRAINDICATIONS:
A. Patients with known intolerance to Fentanyl
B. Use caution if patient is pregnant, pregnancy risk category C

SIDE EFFECTS AND NOTES:
A. Respiratory depression
B. Decreased BP; monitor BP before and after administration. Systolic BP must be over 110mmHg
C. Decreased level of consciousness; watch for respiratory depression.
D. Decreased heart rate.
E. Have naloxone available to reverse over administration.
F. May follow administration with Zofran for nausea.
G. A dose of 100mcg is approximately equivalent to 10mg of morphine.

ADULT DOSING:
50mcg given slowly IV/IM/IO/IN titrated to patient’s condition and response.
RSI: may administer 1-2 mcg/kg IV/IO

PEDIATRIC DOSING:
2-5mcg/kg IV/IM/IO/IN
CLASS: A

PROTOCOL(S) USED IN: Altered Mental Status, Hypoglycemia

PHARMACOLOGY AND ACTIONS:
A. Increases blood glucose concentration by converting liver glycogen to glucose.
B. Parenteral administration of glucagon produces relaxation of the smooth muscle of the stomach, duodenum, small bowel and colon.

INDICATIONS:
A. Hypoglycemia when IV access is unavailable or delayed.

CONTRAINDICATIONS:
None

SIDE EFFECTS AND NOTES:
A. N/V and generalized allergic reactions have been reported.
B. Glucagon should not be used at concentrations greater than 1 unit (1mg).
C. Should not be used unless solution is clear and of water-like consistency.

ADULT DOSING:
A. Give 1 unit (1mg) of glucagon IM.
B. If no effect in 8-10 minutes, repeat 1 unit.
C. IV glucose must be given if patient fails to respond to glucagon

Pediatrics: 0.5 mg IM
CLASS: A

PROTOCOL(S) USED IN: Hypoglycemia

PHARMACOLOGY AND ACTIONS:
Provides a quickly absorbed form of glucose to increase blood glucose levels.

INDICATIONS:
Conscious patient with suspected hypoglycemia.

CONTRAINDICATIONS:
A. Decreased level of consciousness
B. Active vomiting

SIDE EFFECTS AND NOTES:
Duration of effect is limited; patient should consume foods high in carbohydrates as soon as possible.

ADULT DOSING:
15-30 gm orally. May be repeated until desired effects have been achieved.

PEDIATRIC DOSING:
Same as adult
Haloperidol (Haldol®) – 20.142

CLASS: A

PROTOCOL(S) USED IN: Psychiatric Emergencies

PHARMACOLOGY AND ACTIONS:
A. Haloperidol has similar pharmacologic properties to those in phenothiazines.
B. It is thought to block dopamine (type 2) receptors in the brain, altering mood and behavior.

INDICATIONS:
A. Acute psychotic episodes
B. Emergency sedation of severely agitated or delirious patients.

CONTRAINDICATIONS:
A. CNS depression
B. Coma
C. Known hypersensitivity
D. Pregnancy
E. Severe liver or cardiac disease.

SIDE EFFECTS AND NOTES:
A. Dose-related extrapyramidal reactions
B. Hypotension
C. Orthostatic hypotension
D. Nausea, vomiting
E. Allergic reactions
F. Blurred vision

ADULT DOSING:
A. 2-5mg IM or 1-5mg IV every 4-8 hours as needed

PEDIATRIC DOSING:
A. 0.5mg IM
OLMC REQUIRED:
Second 5 gram dose.

SUPPLIED: 5 grams powder in vial for reconstitution with 200 ml NS.

PHARMACOLOGY AND ACTIONS:
Hydroxocobalamin (vitamin B12a) is an effective antidote in the treatment of cyanide poisoning based on its ability to bind cyanide ions. Each Hydroxocobalamin molecule can bind one cyanide ion to form cyanocobalamin (vitamin B12), which is then excreted in the urine. Cyanide is an extremely potent toxic poison. In the absence of rapid and adequate treatment exposure to a high dose of cyanide can result in death within minutes due to inhibition of cytochrome oxidase resulting in arrest of cellular respiration.

INDICATIONS:
Cyanide poisoning or smoke inhalation with suspected cyanide poisoning due to the presence of coma, persistent hypotension or cardiorespiratory arrest.

CONTRAINDICATIONS:
Do not administer Hydroxocobalamin and Sodium Thiosulfate to the same patient.

PRECAUTIONS:
Hydroxocobalamin has physical (particulate) and chemical incompatibilities with many medications and it is best to administer other drugs or products (e.g. blood) through a separate intravenous line.

SIDE EFFECTS AND NOTES:
A. The most frequently occurring side effects are chromaturia (red colored urine) and erythema (skin redness) which occur in nearly all patients.
B. Other reported serious side effects include allergic reactions, temporary increases in blood pressure, nausea, headache and infusion site reactions.
C. Because of its deep red color, Hydroxocobalamin has also been found to interfere with certain laboratory tests based on light absorption including co-oximetric measurements or carboxyhemoglobin, methemoglobin and oxyhemoglobin.

ADULT DOSING:
Cyanide poisoning or smoke inhalation with suspected cyanide poisoning -
5 grams IV or IO over 15 minutes. Vial should be reconstituted with 200 ml of normal saline. Contact OLMC regarding second dose. Monitor for clinical response.

PEDIATRIC DOSING:
Cyanide poisoning or smoke inhalation with suspected cyanide poisoning -
70 mg / kg IV or IO over 15 minutes. Vial should be reconstituted with 200 ml of normal saline. Contact OLMC regarding second dose. Monitor for clinical response.
Ipratropium Bromide

**OLMC REQUIRED:** No

**SUPPLIED:** 0.5 mg / 2.5 ml vial

**PHARMACOLOGY AND ACTIONS:**
Ipratropium is an atropine derivative used for inhalation therapy. For severe asthma, Ipratropium taken in addition to a short acting beta agonist (such as Albuterol) can provide greater bronchodilation and clinical benefit than the beta agonist alone. It has no anti-inflammatory effects and does not decrease bronchial hyper-responsiveness.

**INDICATIONS:**
As a supplement to Albuterol in patients with asthma and COPD.

**CONTRAINDICATIONS:**
*Do not use in patients with severe glaucoma.*

**PRECAUTIONS:**
Ipratropium in the meter dose inhaler and auto-inhaler formulations should not be administered to individuals allergic to soy lecithin or related food products (e.g. soy beans, peanuts). The nebulized formulation may be administered to these patients.

**SIDE EFFECTS AND NOTES:**
A. Dry mouth.
B. Pharyngeal irritation.
C. Increased intra-ocular pressure in glaucoma patients.

**ADULT DOSING:**
- **Asthma/ COPD -**
  - **Duo Neb:** 0.5 mg via nebulizer with Albuterol.

**PEDIATRIC DOSING:**
- **Same as adult dosing**
CLASS: A

PROTOCOL(S) USED IN: RSI, Altered Mental Status

PHARMACOLOGY AND ACTIONS:
A. Sedative/dissociative analgesia
B. Generalized CNS depression
C. The exact mechanism of action is unknown; it acts on the cortex and limbic receptors producing dissociative analgesia and sedation.

INDICATIONS:
Sedation during RSI.
Probable Excited Delirium

CONTRAINDICATIONS:
A. Known hypersensitivity.
B. Hypertension
C. Stroke
D. Intracranial mass or hemorrhage

SIDE EFFECTS AND NOTES:
A. Respiratory depression
B. Laryngospasm
C. Emergence Delirium

ADULT DOSING:
- Probable excited delirium: Ketamine 4 mg/kg IM or 1 mg/kg IV
- RSI Induction dose:
  o Ketamine 1-2 mg/kg IV push. Single max dose of 200 mg.
  o Continued sedation and analgesia: Ketamine 0.5-1 mg/kg IV.

PEDIATRIC DOSING:
Same as adult
CLASS: A

PROTOCOL(S) USED IN: ACLS, RSI

PHARMACOLOGY AND ACTIONS:
A. Depresses automaticity of Purkinje fibers thus increasing ventricular fibrillation threshold.
B. Decreases conduction rate and force of contraction mainly at toxic levels.
C. Single bolus effect disappears in 10-20 minutes due to redistribution in the body.
D. Metabolic half-life is about 2 hours; toxicity develops with repeated doses.

INDICATIONS:
A. Ventricular tachycardia or suspected ventricular tachycardia if clinical condition is not rapidly deteriorating.
B. Recurrent ventricular fibrillation
C. Following successful defibrillation.
D. Pre-paralytic for RSI
E. Possible treatment of warning PVCs in suspected AMI with doctor’s orders only.

CONTRAINDICATIONS:
A. Supraventricular dysrhythmias
B. Atrial fibrillation or flutter
C. 2\textsuperscript{nd} or 3\textsuperscript{rd} degree heart blocks
D. Hypotension

SIDE EFFECTS AND NOTES:
A. Seizures, slurred speech, AMS
B. Maintenance infusion should be reduced by 50% in patients over 70 years old, hepatic failure, CHF or shock.
C. Routine use of Lidocaine for prophylaxis and prevention of ventricular dysrhythmias in patients suspected of having an AMI IS NOT RECOMMENDED.

ADULT DOSING:
A. Cardiac Arrest VT/VF, VT with pulse:
   - 1-1.5mg/kg IVP
   - May repeat with .5-.75mg/kg every 5-10 minutes up to 3mg/kg
   - Consider drip post ROSC
   - Drip: 1-4mg/min. Mix 1gm in 250ml of D5W and run at:

<table>
<thead>
<tr>
<th>1mg/min</th>
<th>2mg/min</th>
<th>3mg/min</th>
<th>4mg/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 µdrops/min</td>
<td>30 µdrops/min</td>
<td>45 µdrops/min</td>
<td>60 µdrops/min</td>
</tr>
</tbody>
</table>

B. PVCs
   - 0.5-1.5mg/kg IVP
   - May repeat with .5-1.5mg/kg every 5-10 minutes up to 3mg/kg.
   - Start drip ASAP
C. Preparalytic (RSI)
   - 1-1.5mg/kg IV
D. If the procedure is performed on a conscious patient, immediately following placement of the IO needle, administer **0.5 mg/kg 2% lidocaine (not to exceed 50 mg)** slowly through the IO site. Wait approximately 30–60 seconds before flushing with normal saline.

**PEDIATRIC DOSING:**
- Preparalytic (RSI)
  - 1.5-2mg/kg IV up to 6 years old
CLASS: A

PROTOCOL(S) USED IN: Seizure, Cardiac Pacing

PHARMACOLOGY AND ACTIONS:
A. Benzodiazepine with antianxiety and sedative effects.
B. Anticonvulsant

INDICATIONS:
A. Pre-anesthetic medication
B. Sedation
C. Relief of anxiety

CONTRAINDICATIONS:
A. Hypersensitivity
B. Acute narrow-angle glaucoma

SIDE EFFECTS AND NOTES:
A. Apnea, N/V, drowsiness, restlessness, confusion, delirium, HTN, hypotension
B. Class D pregnancy category; may cause fetal damage

ADULT DOSING:
Status epilepticus
2-4mg IM or IV over 2-5 minutes; may repeat in 10-15 minutes. Max dosing is 8mg
Pacing
1-2mg IV
Severe Anxiety
1 mg IN, IM, or slow IV

PEDIATRIC DOSING:
Status epilepticus
Pediatric
1. Consider Ativan (28 days to 12 years) dose: 0.05-0.1mg/kg IV/IO/IM over 2-5 mins.
   i. IV diluted 1:1 with NS
   ii. If still seizing after 5-10mins you can repeat dose once
CLASS: A ACLS  Class: B Seizure and Asthma

PROTOCOL(S) USED IN: ACLS, Seizure, Asthma

PHARMACOLOGY AND ACTIONS:
A. CNS Depressant
B. Stabilizes muscle cell membranes by interacting with the sodium/potassium exchange system.
C. Smooth muscle relaxant
D. Vasodilator
E. Bronchodilator

INDICATIONS:
A. Severe refractory VF
B. Torsades
C. Eclampsia

CONTRAINDICATIONS:
A. Renal Disease
B. Heart Block

SIDE EFFECTS & SPECIAL NOTES
A. Hypotension
B. Asystole
C. Respiratory & CNS Depressant

ADULT DOSING:
Refractory V Fib / Torsades -
1.0-2.0 grams diluted in 10ml NS IV/IO over 1-2 minutes.

Tachycardia with a pulse: Wide QRS Irregular Rhythm
1.0-2.0 grams diluted in 10ml NS IV/IO over 5 minutes.

Eclampsia -
4.0-6.0 grams diluted in 10ml NS IV/IO over 1-2 minutes.

Asthma
(usual dose is 1-2 grams diluted to 10cc in NS IV). Administer slowly.
(Contraindicated in the hypotensive pt.).

PEDIATRIC DOSING:
CLASS: A

PROTOCOL(S) USED IN: RSI, Seizure, Cardioversion, Pacing

PHARMACOLOGY AND ACTIONS:
A. Sedative/hypnotic benzodiazepine
B. Generalized CNS depression
C. Therapeutic effects include short term sedation and postoperative amnesia

INDICATIONS:
A. Status seizure (any seizure that has lasted longer than 2 minutes or two consecutive seizures without regaining consciousness)
B. Sedation and amnesia during RSI, cardioversion and cardiac pacing

CONTRAINDICATIONS:
A. Hypersensitivity or cross sensitivity with other benzodiazepines
B. Acute narrow angle glaucoma
C. Shock
D. Comatose patients or those with pre-existing CNS depression
E. Severe, uncontrolled pain
F. Pregnancy or lactation

SIDE EFFECTS AND NOTES:
A. Respiratory depression
B. HA, excess sedation, drowsiness, agitation
C. Blurred vision
D. Cardiac arrhythmias
E. N/V, rashes
F. Increased risk of hypotension with antihypertensives, acute ingestion of alcohol or nitrates

ADULT DOSING:
Seizures/Pacing -
1. Administer midazolam 2 - 5 mg IM. May repeat to a maximum dose of 10 mg for seizures lasting longer than five minutes.
2. If an IV is established and still seizing, may administer midazolam 2.5 mg IV/IO. May repeat to a maximum dose of 10 mg for seizures lasting longer than five minutes.

Chemical restraint -
2mg IV or IM.

Pre-medication for RSI -
0.1mg/kg IV if BP is >80mmHg

Sedation after intubation & for induced hypothermia-
1-5mg IV if BP is >80mmHg.
PEDIATRIC DOSING:

Seizures -
1. Administer midazolam 0.1 mg/kg IV/IO to a maximum initial dose of 2.5 mg. May repeat to a maximum dose of 5 mg for seizures lasting longer than five minutes.

2. If no IV access, administer midazolam 0.2 mg/kg IM to a maximum initial dose of 2.5 mg. May repeat to a maximum dose of 5 mg.

Pre-medication for RSI -
0.1 mg/kg IV/IO not to exceed 2mg

Sedation after intubation with or without paralytics -
0.1 mg/kg IV not to exceed 2mg.
CLASS: A

PROTOCOL(S) USED IN: ACLS, Trauma, RSI, Amputation, Burns, Chest pain, CHF

PHARMACOLOGY AND ACTIONS:
A. Analgesic
B. Peripheral vasodilator
C. Pupil constriction
D. Respiratory depressant
E. Cardiac effect of vasodilation: decreases myocardial oxygen consumption, decreases left ventricular end-diastolic pressure, decreases cardiac workload, may decrease incidence of dysrhythmias.

INDICATIONS:
A. Chest pain not relieved by NTG
B. Pulmonary edema
C. Extremity fractures in absence of any head, chest, or abdominal injuries.
D. Back and neck injuries when sedation/pain relief are necessary to prevent a patient from moving around and potentially injuring themselves.

CONTRAINDICATIONS:
A. Known allergy to morphine or sulfates (Sulfa drugs are not sulfates)
B. Hypotension
C. Head or abdominal injuries
D. Patients with respiratory difficulties except for pulmonary edema
E. Major blood loss
F. Decreased level of consciousness

SIDE EFFECTS AND NOTES:
A. Respiratory depression
B. Decreased BP
C. Decreased level of consciousness
D. Decreased heart rate
E. N/V
F. Have naloxone available to reverse over administration
G. Allergic reactions
H. May follow administration with Zofran for nausea

ADULT DOSING:
Pain - Musculoskeletal injuries, burns, chest pain -
2-10 mg IV/IM/OI/IN. Repeat every 3-5 to max of 20 mg.

PEDIATRIC DOSING (< 20kg):
Pain - Musculoskeletal injuries, burns, chest pain -
0.1-0.2 mg / kg IV/IO/IM/IN. Do not exceed adult dosing.
CLASS: A

PROTOCOL(S) USED IN: Altered mental status

PHARMACOLOGY AND ACTIONS:
A. Narcotic antagonist
B. Competitively binds to narcotic sites, but exhibits almost no pharmacologic activity of its own.
C. Duration of action is 30-80 minutes.

INDICATIONS:
A. Reversal of narcotic overdose
B. Coma of unknown etiology

CONTRAINDICATIONS:
None noted

SIDE EFFECTS AND NOTES:
A. Acute withdrawal symptoms in addicted patients
B. Be prepared to restrain patient
C. Titrate dosing to keep patient awake, responsive and free from respiratory depression, but somewhat groggy.
D. Patients who have received Narcan must be transported to the hospital because coma may recur when Narcan wears off.

ADULT DOSING:
Reversal of opioid effects, coma of unknown etiology –
0.4-2mg IV/IM/IN/IO/SQ/ET to a max dose of 4mg, initial dose titrated to patient’s respirations.
*if no response, repeat 2mg dose up to 4mg
*larger and repeated doses may be required to reverse Darvon overdose

PEDIATRIC DOSING:
If suspected opiate overdose
Naloxone 0.1 mg/kg IV/IO/IM/ IN to a maximum of 2 mg.
CLASS: A

PROTOCOL(S) USED IN: ACLS, Chest Pain

PHARMACOLOGY AND ACTIONS:
A. Vasodilator
B. Decreases peripheral resistance
C. Generalized smooth muscle relaxation
D. Reduces venous tone

INDICATIONS:
A. Chest, arm, neck pain thought to be related to coronary ischemia.
B. Angina
C. Control of hypertension in angina or acute MI
D. Pulmonary edema

CONTRAINDICATIONS:
A. Hypotension
B. Hypovolemia
C. ICP
D. Aortic Stenosis
E. Severe bradycardia or tachycardia
F. Patients who have taken Viagra® (sildenafil citrate) or Levitra® (vardenafil HCl) within 24 hours, or who have taken Cilais® (tadalafil) within 48 hours. Contact OLMC for direction.

SIDE EFFECTS AND NOTES:
A. Common side effects are headache, flushing, dizziness or burning under the tongue.
B. Hypotension; IV line should be established prior to administration
C. Reflex tachycardia
D. Syncope
E. May be effective in relieving chest pain due to esophageal spasm
F. Therapeutic effect is enhanced but adverse effects are increased when patient is upright.
G. NTG Loses potency easily; should be stored in a dark glass container with tight lid and not exposed to heat.

ADULT DOSING:
Chest pain, pulmonary edema -
A. 0.4 mg SL every 3-5 minutes up to 3 doses as long as systolic BP is greater than 100 mmHg.

Suspected ischemic chest pain, unstable angina, acute pulmonary edema, acute MI -
A. 5mcg/min IV infusion; titrate to effect

PEDIATRIC DOSING:
CLASS: A

PROTOCOL(S) USED IN: Nausea & Vomiting

PHARMACOLOGY AND ACTIONS:
Selective antagonist of a specific type of serotonin receptor located in the CNS at the chemoreceptor trigger zone and in the peripheral nervous system on nerve terminals of the vagus nerve. Drugs blocking action may occur at both sides.

INDICATIONS:
Prevention and control of nausea and vomiting.

CONTRAINDICATIONS:
Known hypersensitivity to Zofran or similar medications. Caution in patients with hepatic impairment.

SIDE EFFECTS AND NOTES:
A. Headache, malaise, fatigue, dizziness, fever, sedation
B. Extrapyramidal symptoms; have Benadryl available
C. Pregnancy risk category B

ADULT DOSING:
Nausea & vomiting -
4mg IM/IN or IV over 2-5 minutes

PEDIATRIC DOSING:
A. Ondansetron use in patients under 2 years of age requires OLMC consultation.
B. For children < 40 kg administer Ondansetron 0.1mg/kg via slow IV push over 2 minutes up to a total maximum IV dose of 4mg.
CLASS: A

PROTOCOL(S) USED IN: All when indicated

PHARMACOLOGY AND ACTIONS:
Raises the amount of oxygen in the blood and the amount delivered to the tissues.

INDICATIONS:
A. Suspected hypoxia or respiratory distress from any cause.
B. Acute chest pain where MI is suspected.
C. Shock from any cause
D. Major trauma
E. Carbon monoxide poisoning

CONTRAINDICATIONS: None

SIDE EFFECTS AND NOTES:
A. DO NOT WITHHOLD OXYGEN from patients with COPD. Be prepared to assist ventilations if needed. Initial flow should be no greater than 2 lpm to start.
B. Patient should be breathing adequately on their own, if not, assist with BVM.
C. Oxygen supports combustion, use caution.
D. Oxygen toxicity is not a hazard from acute administration.
E. Non-humidified O2 is drying and irritating to mucous membranes.

<table>
<thead>
<tr>
<th>DOSAGE</th>
<th>INDICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Flow (1-2 lpm)</td>
<td>Patients with chronic lung disease</td>
</tr>
<tr>
<td>Moderate Flow (4-6 lpm)</td>
<td>Precautionary use for trauma, chest pain</td>
</tr>
<tr>
<td>High Flow (10-15 lpm)</td>
<td>Severe respiratory distress</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OXYGEN THERAPY</th>
<th>Device</th>
<th>Flow Rate</th>
<th>O2 % Inspired Air</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Flow</td>
<td>Nasal Cannula</td>
<td>1-2 lpm</td>
<td>25-28%</td>
</tr>
<tr>
<td>Moderate Flow</td>
<td>Nasal Cannula</td>
<td>6 lpm</td>
<td>50-60%</td>
</tr>
<tr>
<td>High Flow</td>
<td>Non-rebreather mask</td>
<td>10-25 lpm</td>
<td>90+%</td>
</tr>
</tbody>
</table>
CLASS: C

PRTOCOL(S) USED IN: Childbirth

PHARMACOLOGY AND ACTIONS:
A. Hormone which increases electrical and contractile activity in uterine smooth muscle.
B. Can initiate or enhance rhythmic contractions of the uterus.
C. Exhibits rapid onset with a very short half-life, rapid inactivation and excretion.

INDICATIONS:
Control of post-partum hemorrhage

CONTRAINDICATIONS:
Rule out multiple fetuses before administration

SIDE EFFECTS AND NOTES:
A. Administration should follow delivery of placenta.
B. In large doses, oxytocin exhibits a transient, but marked vasodilating effect and reflex tachycardia.
C. Cardiac dysrhythmias may be precipitated or aggravated by oxytocin.

ADULT DOSING:
10 USP units (10mg) IM x 1; if no response Contact Medical Control.
OLMC REQUIRED: For IV use.

SUPPLIED: 600 mg / 2 ml auto-injector, 1 gm powder vial – reconstitute with 20 ml NS

PHARMACOLOGY AND ACTIONS:
The principal action of Pralidoxime is to reactivate cholinesterase which has been inactivated by an organophosphate pesticide or related compound. The drug’s most critical effect is in relieving paralysis of respiratory muscles. Atropine is always required concurrently to block the effect of acetylcholine.

INDICATIONS:
A. As an antidote in the treatment of poisoning due to organophosphate pesticides and chemicals.
B. Control of overdose by anticholinesterase drugs (e.g. treatment of myasthenia gravis).

CONTRAINDICATIONS:
None in the emergency setting.

PRECAUTIONS:
A. Rapid IV injection may cause tachycardia, laryngospasm, muscle rigidity and transient neuromuscular blockade. Administration should be done slowly and preferably by infusion.
B. Pralidoxime is a relatively short acting drug, repeat dosing may be necessary.

SIDE EFFECTS AND NOTES:
Dizziness, blurred vision, diplopia, headache, drowsiness, nausea, tachycardia and muscle weakness have been reported following administration.

ADULT DOSING:
Refer to Haz-Mat Protocol – Organophosphate Poisoning for dosing.

PEDIATRIC DOSING:
Refer to Haz-Mat Protocol – Organophosphate Poisoning for dosing.
CLASS: A

PROTOCOL(S) USED IN: RSI

PHARMACOLOGY AND ACTIONS:
Non-depolarizing neuromuscular blocking agent

INDICATIONS:
Paralysis to facilitate rapid sequence intubation

CONTRAINDICATIONS:
Known hypersensitivity

SIDE EFFECTS AND NOTES:
A. Use caution in patients with impaired hepatic or respiratory function or severe obesity.
B. Arrhythmia, tachycardia, N/V, bronchospasm, hypotension, HTN, rash or edema.
C. Must be able to ventilate patient
D. Must be accompanied by sedation
E. Pregnancy Category B; only use if potential benefits justifies the potential risk to the fetus.

ADULT DOSING:
Paralytic agent – 1 mg/kg IV/IO
Maintenance - 0.3-0.5 mg/kg IV

PEDIATRIC DOSING:
Same as adult
CLASS: A

PROTOCOL(S) USED IN: ACLS, Overdose

PHARMACOLOGY AND ACTIONS:
A. An alkalotic solution which neutralizes acids found in the blood.
B. Acidosis depresses cardiac contractility, and the cardiac response to catecholamine and makes the heart more likely to fibrillate.

INDICATIONS:
A. To reverse acidosis found during cardiac arrest and near-drowning victims.
B. Make the heart more receptive to conversion from VF, asystole, or PEA by normalizing the pH.
C. For alkalinization of urine in certain poisoning & overdoses.

CONTRAINDICATIONS: None

SIDE EFFECTS AND NOTES:
A. Should not be given in with catecholamine or calcium.
B. May increase cerebral acidosis, especially in diabetics who are ketotic.
C. Metabolic alkalosis which is impossible to reverse.
D. In respiratory arrest without cardiac arrest, the treatment of choice is ventilation, no sodium bicarbonate unless cardiac arrest has occurred and the patient does not respond to adequate ventilation or other standard ACLS treatment modalities.

ADULT DOSING:
Cardiac arrest- 1mEq/kg initially followed by 0.5mEq/kg every 10 minutes

Tricyclic Overdose:
If patient exhibits arrhythmias or a widening QRS complex administer sodium bicarbonate 1 mEq/kg IV/IO.

PEDIATRIC DOSING:
Same as adult
CLASS: A

PROTOCOL(S) USED IN: RSI

PHARMACOLOGY AND ACTIONS:
A. Short acting depolarizing skeletal muscle relaxant.
B. Binds to cholinergic receptors in the motor neuron endplate to cause muscle depolarization (fasciculations) followed by paralysis.
C. Complete paralysis occurs with 1 minute; recovery usually seen within 4-6 minutes.
D. Has no effect of consciousness or pain threshold.

INDICATIONS:
Paralysis to facilitate rapid sequence intubation

CONTRAINDICATIONS:
A. Acute narrow angle glaucoma
B. Penetrating eye injuries
C. Burns or crush injuries >12-24 hours
D. Use caution in patients with kidney failure or undiagnosed neuromuscular disease or skeletal muscle myopathy such as Duchenne’s Muscular Dystrophy.

SIDE EFFECTS AND NOTES:
A. May cause malignant hyperthermia, ventricular dysrhythmias, bradycardia in pediatrics, hyperkalemia, hypotension, increased intraocular pressure and ICP.
B. Histamine release may occur.
C. Bradycardia is usually seen in patients under 5 years old and will generally respond to oxygenation and atropine.
D. Ventricular dysrhythmias may be treated with oxygenation and lidocaine.

ADULT DOSING:
Initial Dose- 1.5mg/kg IV/IO; a second dose may be given if paralysis is no achieved within 60-120 seconds of initial administration.

PEDIATRIC DOSING:
Initial Dose- 2mg/kg IV/IO
CLASS: A

PROTOCOL(S) USED IN: Altered Mental Status, Seizure

PHARMACOLOGY AND ACTIONS:
A. Vitamin commonly referred to as vitamin B1.
B. B1 is required for the conversion of pyruvic acid to acetyl-coenzyme A.
C. If thiamine deficiency occurs, the brain cannot obtain glucose to use as energy.
D. Chronic alcoholism or starvation interferes with the absorption, intake, and utilization of thiamine.

INDICATIONS:
A. Administered with D50 in patients suspected of malnutrition of chronic alcoholism.
B. Coma of unknown origin, especially if alcohol may be involved.
C. Delirium tremens

CONTRAINDICATIONS:
Known hypersensitivity

SIDE EFFECTS AND NOTES:
A. There may be a few cases of hypersensitivity to thiamine

ADULT DOSING:
100mg IV or IM if IV access cannot be obtained.
CLASS: A

PROTOCOL(S) USED IN: ACLS

PHARMACOLOGY AND ACTIONS:
A. Vasopressor that stimulates smooth muscle V1 receptors.
B. Peripheral vasoconstrictor, but provides some cerebral and cardiac dilation.
C. Naturally occurring antidiuretic hormone.
D. Half-life is 10-20 minutes

INDICATIONS:
VF and pulseless VT

CONTRAINDICATIONS:
None in cardiac arrest

SIDE EFFECTS AND NOTES:
A. May increase peripheral vascular resistance and provoke cardiac ischemia and angina.

ADULT DOSING:
40 units IV/IO one time, may be given via ET at same dose.
It is acceptable to return to epinephrine 1 mg every 3-5 minutes.

PEDIATRIC DOSING:
Not indicated in pediatrics.
OLMC REQUIRED: No

SUPPLIED: 10 mg vial of powder and 10 ml vial of diluent solution

PHARMACOLOGY AND ACTIONS:
Vecuronium is a non-depolarizing neuromuscular blocking agent causing skeletal muscle relaxation. It reversibly binds the acetylcholine receptor, blocking the action of acetylcholine. Neuromuscular blockade occurs within 2-3 minutes. Time to recovery is 30-45 minutes. Vecuronium metabolism is 5-35% renal with the remainder done in the liver.

INDICATIONS:
A. For sustained neuromuscular blockade in the intubated patient.
B. As the first line agent for Rapid Sequence Induction in the patient where Succinylcholine is contraindicated.

CONTRAINDICATIONS:
None

PRECAUTIONS:
A. Patients with renal or hepatic failure may experience prolonged paralysis.
B. Vecuronium has no effect on consciousness and must be used with a sedative or induction agent.

SIDE EFFECTS AND NOTES:
A. Vecuronium exhibits minimal side effects and does not substantially affect heart rate or rhythm, systolic or diastolic blood pressure, mean arterial pressure, cardiac output, or systemic vascular resistance.
B. Vecuronium can be used to maintain paralysis even if intubation was performed without Succinylcholine.

ADULT DOSING:
Rapid Sequence Induction -
0.1 mg/kg IV/IO.

PEDIATRIC DOSING:
Same as adults.